Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Harvard Business School
Medtronic
McKinsey
Boehringer Ingelheim

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AIN457

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for AIN457?

AIN457 is an investigational drug.

There have been 51 clinical trials for AIN457. The most recent clinical trial was a Phase 3 trial, which was initiated on January 16th 2018.

The most common disease conditions in clinical trials are Arthritis, Psoriasis, and Arthritis, Psoriatic. The leading clinical trial sponsors are Novartis Pharmaceuticals, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), and Novartis.

There are two US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for AIN457
TitleSponsorPhase
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisNovartis PharmaceuticalsPhase 3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis SuppurativaNovartis PharmaceuticalsPhase 3
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic ArthritisNovartis PharmaceuticalsPhase 3

See all AIN457 clinical trials

Clinical Trial Summary for AIN457

Top disease conditions for AIN457
Top clinical trial sponsors for AIN457

See all AIN457 clinical trials

US Patents for AIN457

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AIN457   Start Trial Substituted pyrimidinone-phenyl-pyrimidinyl compounds CONFLUENCE LIFE SCIENCES, INC. (St. Louis, MO)   Start Trial
AIN457   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Boehringer Ingelheim
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.